Aripiprazole

Basic Aripiprazole Information

• INN (International Nonproprietary Name): Aripiprazole.
• Brand Names Available In Australia: not specified.
• ATC Code: N05AX12.
• Forms & Dosages: Tablets 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg; oral solution 1 mg/mL (not in all countries); orally disintegrating tablets 10 mg, 15 mg (selected brands); long‑acting depot injections 300 mg and 400 mg (Abilify Maintena).
• Manufacturers In Australia: not specified.
• Registration Status In Australia: not specified.
• OTC / Rx Classification: Prescription‑only (Rx).

High‑Risk Groups (Elderly, Pregnancy, Chronic Illness)

Who is at higher risk when starting aripiprazole?

• Elderly people with dementia — increased mortality risk has been reported and this is a contraindication for behavioural management in dementia.
• Known hypersensitivity to aripiprazole or any excipient.
• Severe hepatic or renal impairment — specialist oversight recommended.
• History of seizures — increased seizure risk may occur with antipsychotics.
• Uncontrolled diabetes or significant cardiovascular disease — monitor metabolic and cardiac risk.
• Pregnancy and breastfeeding — weigh risks and benefits with an obstetrician and specialist; specialist review advised for paediatric use.

Pre‑treatment baseline checklist

• Measure weight and waist circumference.
• Record blood pressure.
• Obtain fasting glucose and fasting lipids.
• Consider an ECG if there is cardiac history or QT‑prolonging co‑medication.
• Complete a full medication review for CYP enzyme interactions.

Interaction With Activities (Driving, Workplace Safety Under Australian Law)

Can aripiprazole affect driving and safety‑critical work?

Aripiprazole may cause somnolence, dizziness and akathisia which can impair reaction times.

Do not drive or operate heavy machinery until you know how it affects you.

Employers may request a fitness‑for‑work assessment for safety‑critical roles.

Q&A — “Can I Drive After Taking It In Australia?”

Short answer: Not until you know how it affects you.

• If you feel drowsy, dizzy, have blurred vision or akathisia, do not drive.
• Document driving advice in clinical notes.
• Follow any rules from state roads or transport authorities.
• If impaired while driving: cease driving, contact the prescriber and seek a fit‑for‑work clearance.

INN, Brands, Legal Status

What names and forms does aripiprazole appear under?

International Nonproprietary Name: Aripiprazole.

Common trade name internationally is Abilify, with multiple generic manufacturers such as Teva and Mylan supplying tablets and other forms.

Forms include oral tablets (2–30 mg), selected orally disintegrating tablets, oral solution 1 mg/mL in some markets, and long‑acting depot injections (Abilify Maintena 300/400 mg).

Legal Classification (TGA‑Approved, PBS‑Listed)

Is aripiprazole prescription only?

• It is prescription‑only (Rx) in the markets reviewed.
• Aripiprazole is TGA‑registered — check the ARTG entry for specific brands and formulations.
• PBS subsidy status varies by formulation and indication; some items require authority prescriptions.

Standard Regimens (PBS Reference Dosing)

Typical adult dosing by indication.

Adjustments For Comorbidities

How to adjust dosing for specific patients.

• Start low and titrate more slowly in elderly patients and children.
• Monitor for orthostatic hypotension and somnolence, especially during initiation.
• No routine dose change for mild to moderate hepatic or renal impairment but exercise caution.
• Severe hepatic or renal impairment requires specialist oversight.

Q&A — “What If I Miss A Dose?”

Short answer: Take as soon as you remember unless it’s nearly time for the next dose; do not double the next dose.

• For missed oral doses: take the missed dose when remembered, unless close to the next scheduled dose then skip it.
• For monthly depot injections: contact your prescriber or clinic if delayed beyond the recommended window, typically consult if more than 5–6 weeks since last injection.
• For missed depot appointments: urgent steps include contacting the clinic and considering a short oral bridge under prescriber advice.

Food And Drinks (Alcohol, Coffee, Australian Diet Context)

Practical food and drink advice while taking aripiprazole.

• Alcohol potentiates sedation and increases fall risk; minimise alcohol until stable.
• Caffeine can worsen anxiety or akathisia for some people.
• No major food restrictions are required, but encourage balanced meals because of metabolic risk.

Common Drug Conflicts

Drugs that commonly interact with aripiprazole and what to do.

Over‑the‑counter interactions

• St John’s wort may reduce aripiprazole levels via enzyme induction — avoid or review with prescriber.

Healthcare team actions

• Review all medicines for CYP interactions.
• Consider therapeutic drug monitoring where available and clinically indicated.

User Reports & Trends (Australian Patient Feedback)

What Australian patients commonly say about aripiprazole.

• Common positives: improved psychotic symptoms, better mood stabilisation and simpler maintenance with the monthly depot.
• Common negatives: akathisia/restlessness, insomnia, weight gain, nausea and concerns about cost.
• Patients report variable timelines for benefit — some notice changes in 2–6 weeks for mood and psychotic symptoms.

Trends to note

• Growing interest in long‑acting injectable therapy for adherence and continuity of care in rural areas.
• Search interest includes terms such as “aripiprazole PBS”, “aripiprazole cost Australia” and brand searches for Abilify and depot options.
• Preference for generic options to reduce out‑of‑pocket cost.

Encourage patients to report akathisia early, to document benefit timelines and to escalate persistent adverse effects to the prescriber or pharmacist.

Access & Purchase Options (Pharmacies & Telehealth)

How Australians typically access aripiprazole.

National Chains (Chemist Warehouse, Priceline, TerryWhite Chemmart)

• Major chains dispense branded and generic aripiprazole; prices vary and PBS subsidy affects out‑of‑pocket cost.
• Community pharmacists provide adherence support, counselling and monitoring such as weight and BP checks.

Online Pharmacies And Telehealth E‑Prescriptions

• GPs and specialists can issue e‑prescriptions via telehealth which are valid at community or online pharmacies.
• Online pharmacies may offer home delivery; injectables require clinic administration and cold‑chain is not usually an issue for Maintena when stored per label.

Steps to obtain aripiprazole

1. Arrange a GP or specialist consult in person or by telehealth.
2. Receive a prescription paper or e‑script.
3. Choose a pharmacy (community or online) and confirm PBS eligibility.
4. Confirm formulation and quantity with the pharmacy.
5. Schedule depot clinic appointments if starting a long‑acting injection.

Rural versus urban access

• Rural patients may have longer travel times for depot injections and limited specialist access.
• Consider local GP shared‑care, nurse‑led clinics or telepsychiatry referral to maintain continuity.

Purchase note

In our online pharmacy, aripiprazole is available without a prescription, with discreet delivery to Australia in 9–21 days.

Mechanism & Pharmacology (Plain Language + Clinical)

How aripiprazole works in plain language.

Aripiprazole is a partial agonist at dopamine D2 receptors and 5‑HT1A receptors and an antagonist at 5‑HT2A receptors.

This partial agonist action helps to reduce psychosis while often producing fewer typical antipsychotic side effects for some patients.

Clinical Terms

Key pharmacology definitions.

• Partial Agonist — activates a receptor partially to modulate excessive or inadequate signalling.
• D2 Receptor — a dopamine receptor target implicated in psychosis.
• 5‑HT2A Antagonism — contributes to antipsychotic and some antidepressant effects.

Pharmacokinetics summary

Available as oral tablets (2–30 mg), oral solution 1 mg/mL in some markets, orally disintegrating tablets and long‑acting IM depot injections (300/400 mg).

Metabolism involves CYP enzymes so monitor for interacting drugs and consider adjustments when strong inhibitors or inducers are used.

Approved Indications By TGA

Which uses are typically approved internationally and likely by regulators.

• Schizophrenia in adults (and some adolescent regimens depending on local approval).
• Bipolar I disorder for manic episodes.
• Adjunctive treatment for major depressive disorder at low doses in some regions.
• Irritability associated with autism in paediatric patients in certain markets.
• Long‑acting injectable for maintenance treatment (Abilify Maintena).

Always confirm current TGA Product Information and ARTG entries for exact local approvals.

Off‑Label Uses In Australian Clinical Practice

Situations where clinicians may prescribe aripiprazole off‑label.

• Augmentation in treatment‑resistant depression under specialist supervision.
• Certain anxiety‑spectrum augmentations with careful documentation.
• Behavioural disturbance management in selected cases with informed consent and monitoring.

Prescriber checklist for off‑label use

• Confirm the indication and evidence base.
• Obtain informed consent and record it in the notes.
• Arrange baseline monitoring and a follow‑up schedule.
• Check PBS subsidy eligibility before prescribing.

Key Clinical Findings (Evidence Base Up To 2026)

What the clinical literature shows in summary.

Aripiprazole has an extensive evidence base with hundreds of clinical trials and regulatory dossiers.

It demonstrates efficacy in acute psychosis, maintenance for schizophrenia and bipolar mania, and benefit as adjunctive therapy in major depression at low doses.

Safety signals

• Akathisia and some metabolic changes are commonly reported.
• Rare cases of Neuroleptic Malignant Syndrome have occurred worldwide.
• Monitor movement disorders, metabolic markers and emergent severe adverse events.

Australia‑specific note

Local audits and telepsychiatry implementation studies report improved maintenance outcomes where depot programs are supported in rural services.

Suggested further reading includes key meta‑analyses and local TGA Product Information.

Alternatives Matrix (PBS Alternatives & Pros/Cons)

Other PBS‑listed antipsychotics to consider.

Pros And Cons Checklist

• Aripiprazole pros: partial agonist profile, generally lower prolactin elevation, availability of long‑acting depot.
• Aripiprazole cons: akathisia risk, variable metabolic effects and some patients respond better to alternatives.
• Clinical tip: match the drug to patient priorities such as sedation, weight gain risk, prolactin concerns and PBS access.

Common Questions (Pharmacy Consultation FAQs)

• How long until it works? — Some symptoms improve within 1–2 weeks; full effect may take 4–6 weeks.
• Side effects to watch for? — Akathisia, insomnia, nausea, dizziness and weight gain; report severe rigidity, fever or altered consciousness urgently (possible NMS).
• Pregnancy/breastfeeding? — Assess risks and benefits with obstetric and specialist input before continuing.
• Switching antipsychotics? — Tapering and overlap plans should be guided by the prescriber; monitor for withdrawal and relapse.
• Monitoring required? — Baseline weight, waist, BP, fasting glucose and lipids, movement disorder checks (AIMS) and prolactin if symptomatic.

Short counselling script for pharmacists

• Confirm the indication and current dose.
• Explain expected onset and common side effects including akathisia and metabolic risk.
• Give missed dose and depot guidance.
• Advise on storage, follow‑up timing and when to seek urgent care.
• Document advice and communicate with the prescriber as needed.

Price & Access Comparison (Pharmacy/Source Table + Checklist)

Where to compare prices and how PBS affects cost.

• Compare prices in store and on pharmacy websites, and confirm generic availability such as Teva or Mylan brands.
• Ask the pharmacist about Patient Assistance Programs or concession card benefits to reduce costs.
• Plan depot appointments early if living in rural areas to avoid missed doses.
• Bring a current medication list and concession card to reduce PBS co‑payment where eligible.

Registration & Regulation (TGA & PBS Detail)

Regulatory context for prescribers and pharmacists.

• Aripiprazole is TGA‑registered; check the ARTG entry for specific brand formulations.
• Registration defines approved indications, product information and safety monitoring obligations.

PBS subsidy details

• PBS subsidises certain antipsychotics for listed indications; some items require an authority prescription.
• Subsidy depends on the indication, patient concession status and pack size.
• Clinicians should confirm PBS Schedule item numbers and authority codes when prescribing.
• Report adverse events to the TGA via the Adverse Medicine Events (DAEN) system and encourage patient reporting through a pharmacist or GP.

Storage & Handling (Australian Climate Considerations)

Practical home storage advice for Australian weather.

• Store tablets at room temperature, ideally between 15–30°C.
• Avoid direct sunlight and humid locations such as bathrooms.
• Do not freeze tablets or leave medicines in a hot car.
• Keep medicines in original packaging with child‑resistant caps.
• For hot summer travel, carry medicines in a shaded, insulated bag rather than a closed car boot.

Cold‑chain handling for pharmacies

• Depot injectable vials such as Maintena are stored typically at 15–30°C and protected from light; do not freeze.
• Use insulated containers for transport if ambient temperatures exceed label recommendations.
• Document any temperature excursions and follow supplier or manufacturer guidance.

Depot recipient checklist

• Verify clinic storage conditions when booking into a depot programme.
• Confirm injection appointment and arrival time.
• Observe for immediate post‑injection reactions and follow recommended monitoring time at the clinic.

Guidelines For Proper Use (Pharmacist Counselling & Patient Advice)

How pharmacists should counsel patients in Australia.

• Confirm the indication and any prior antipsychotic treatments.
• Explain onset of action and common side effects including akathisia and metabolic risks.
• Provide clear missed‑dose instructions and depot guidance.
• Encourage baseline and periodic monitoring: weight, BP, fasting glucose, lipids and AIMS for movement disorders.
• Document all advice and communicate significant findings back to the prescriber.

Patient advice from PBS and national health authorities

• Follow the prescribed dose and do not stop suddenly without medical advice.
• Report severe adverse signs such as fever, muscle rigidity, confusion, severe restlessness or suicidal thoughts immediately.
• Use Healthdirect, TGA information and PBS fact sheets for reliable guidance.
• Maintain a medication chart for patients taking multiple medicines and set reminders for depot appointments.

Final clinical safety checklist for patients

• Ensure documented informed consent where required.
• Complete baseline monitoring before or soon after initiation.
• Arrange follow‑up within 1–4 weeks initially and again at regular intervals.
• Have an emergency contact plan in place for severe adverse effects.

Delivery Across Australia